Diabetes

By Tammy Lovell 09:34 am September 4, 2019
Liva Healthcare has secured €603,405 in funding from the EU Horizon 2020 programmes to be part of the "Impact Diabetes Bump 2 Baby" (IDB2B) research project.  The digital health coaching app, headquartered in London and Copenhagen, will work toward finding the best way to treat mothers at risk of developing Type 2 diabetes. Health coaching will be provided via the Liva Healthcare app to women...
By Laura Lovett 12:03 pm August 14, 2019
This morning Solera Health, a digital marketplace for benefits and chronic disease management programs, is offering a new Diabetes Prevention Program (DPP) in American Sign Language (ASL) to people in the Kansas City area.  The program, created by the Johnson County Department of Health and Environment, will service adults living with hearing impairments in the region who are covered by a local...
By Cara Dartnell-Steinberg 05:25 am August 14, 2019
People at risk of developing Type 2 diabetes will receive digital support through a scheme that aims to prevent the condition from developing in England, part of the NHS Long Term Plan released at the beginning of the year. WHAT HAPPENED With the decision to extend this programme, 40,000 places on the Diabetes Prevention Programme (DPP) will be delivered digitally. The first patients to benefit...
By Jonah Comstock 03:04 pm August 9, 2019
In Dexcom’s latest earnings report, executives reported not only growing revenues and sales volume for the company, but a sense that the whole category of CGMs has arrived and is transforming diabetes care for the better, noting trends observed at the recent annual meeting of the American Diabetes Association. “We have been on record for years telling that the future is ‘CGM First’ and we believe...
By Dave Muoio 03:23 pm July 17, 2019
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning. Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
By Cara Dartnell-Steinberg 09:02 am July 15, 2019
Gone are the days of endless finger pricks to test blood glucose levels and complicated mental calculations to deduce carbohydrate ratios with insulin. The growth of people with diabetes by 314 million in the last 34 years has created an ever-expanding market in diabetes management products. Consumers are now inundated with new technology streamlining lives with less needles and more real-time...
By Dave Muoio 11:57 am July 1, 2019
One Drop’s wireless blood glucose monitor is now being sold in certain US Apple Stores, according to a release from the company. One Drop’s platform, which is integrated with Apple’s Health Records, allows iPhone users to more conveniently check their glucose levels and share that data, alongside the rest of their personal health record, with providers. Additionally, purchase of the system at an...
By Dave Muoio 12:05 pm June 28, 2019
Months after the first rumors began to swirl, chronic disease management startup Livongo Health has officially filed for an IPO on the Nasdaq Global Select Market. The company has not yet determined a price range or the number of shares going on offer. Morgan Stanley & Co., Goldman Sachs & Co. and JP Morgan Securities will serve as the lead book runners. Sources close to Livongo told...

Screengrab of the Wellthy Therapeutics website.

By Dean Koh 11:28 pm June 12, 2019
At the 79th Annual Scientific Sessions of the American Diabetes Association in San Francisco, pharma giant Roche and India-based digital therapeutics company Wellthy Therapeutics presented real world data of improved diabetes care outcomes in a South Asian population when patients followed prescribed plan of medication and lifestyle modification in conjunction with a combination therapy of self-...
By Dave Muoio 02:55 pm May 28, 2019
Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range. Collected from nearly 8 million days of recorded system use and announced by Medtronic today in a press release, the new findings also suggest that this rate increased further for those who employed...